Oncology and Targeted Cancer Therapy
Research activity includes locally advanced and metastatic non-small cell lung cancer, with interest in tumors driven by EGFR tyrosine kinase inhibitor resistance as well as cancers carrying BRAF and/or NRAS mutations.
- Non-small cell lung cancer
- EGFR-resistant disease
- BRAF and NRAS mutation-positive tumors
- Advanced solid tumors
The portfolio also covers investigational oral anticancer agents for molecularly defined cancer subgroups.
Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disease
A major focus is EBV-associated lymphoproliferative disease after solid organ transplantation or allogeneic hematopoietic cell transplantation, including cases involving the central nervous system and disease forms where standard first-line treatment is unsuitable.
- EBV+ PTLD
- EBV+ CNS PTLD
- CD20-negative EBV-related disease
- EBV-associated sarcomas
Therapeutic interest extends to EBV-specific cytotoxic T lymphocyte approaches for post-transplant complications.
Rare Genetic Disorders and Developmental Conditions
Clinical research also addresses X-linked hypohidrotic ectodermal dysplasia, with attention to early-life intervention and restoration of sweating function in affected male subjects.
- XLHED
- EDA null mutation
- Intra-amniotic therapy
This area reflects an interest in rare inherited conditions with distinct developmental and physiological manifestations.
Smoking Cessation and Nicotine Dependence
One research stream focuses on smoking urge reduction in moderate smokers, including evaluation of a nicotine lozenge for craving control in non-smoking settings.
- Smoking cessation
- Nicotine craving
- Tobacco dependence
The therapeutic interest lies in symptom relief and support for behavioral change related to tobacco use.
Early-Stage Anticancer Development
Additional studies examine the safety and tolerability of new oral oncology compounds intended for advanced malignancies.
- Investigational anticancer medicines
- Advanced lung cancer
- Molecularly selected solid tumors
These programs support treatment development across precision oncology settings.
